D. Sloan Stribling

Statistics

Publications

Citations

1.7K

H-Index

Active since

1973

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Bioscience Research

The Royal Free Hospital

AstraZeneca (United Kingdom)

University of Aberdeen

D. Sloan Stribling is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and medicinal chemistry.

Publications per year

1973–2010

Publications

Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats

Lauren P. Shearman, Ramon E. Camacho, D. Sloan Stribling et al. · European Journal of Pharmacology · 2003 · 185 citations

Medicine, Endocrinology, Physiology +13

Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat

D. Sloan Stribling, D.J. Mirrlees, Heather Harrison et al. · Metabolism · 1985 · 148 citations

Medicine, Endocrinology, Pharmacology +11

Ghrelin Neutralization by a Ribonucleic Acid-SPM Ameliorates Obesity in Diet-Induced Obese Mice

Lauren P. Shearman, Sheng-Ping Wang, Steffen Helmling et al. · Endocrinology · 2005 · 141 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Protein Kinase C βII Specifically Binds to and Is Activated by F-actin

Gerard C. Blobe, D. Sloan Stribling, Doriano Fabbro et al. · Journal of Biological Chemistry · 1996 · 131 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Linus S. Lin, Thomas J. Lanza, James P. Jewell et al. · Journal of Medicinal Chemistry · 2006 · 122 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

1–5 of 36